Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroblastoma 9Prostatic Neoplasms 3Precancerous Conditions 3Glioma 3Astrocytoma 3Adenomatous Polyposis Coli 3Skin Neoplasms 2Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Stomach Neoplasms 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Eflornithine × Clear all
NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Suspended
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡